ARYx Therapeutics, Inc. (ARYX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 30/100, indicating a weak investment profile with 0 out of 7 criteria passed.
Net income is $33M (loss), growing at -6.8%/yr. Net profit margin is 0% (thin). Gross margin is 98.8% (+43.5 pp trend).
Balance sheet: total debt is $12M with negative equity of -$3M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.01 (adequate). Debt-to-assets is 94.3%. Total assets: $12M.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 25/100 (Fail), Moat 50/100 (Partial), Future ?/100 (Fail), Income ?/100 (Fail).
